Interpace Diagnostics Group, Inc.(IDXG) - 2025 Q3 - Quarterly Results

Financial Performance - Q3 2025 net revenue was $8.8 million, a decrease of 29% from $12.3 million in Q3 2024, but an increase of 22% from $7.3 million on a pro forma basis[5] - Income from continuing operations for Q3 2025 was $1.0 million, compared to $1.8 million in Q3 2024 and a loss of $0.7 million on a pro forma basis[11] - Adjusted EBITDA for Q3 2025 was $1.3 million, down from $2.5 million in the prior year quarter and $0.1 million on a pro forma basis[11] - Cash collections for Q3 2025 totaled $10.0 million, compared to $11.2 million in the prior year quarter[11] - The gross profit percentage for Q3 2025 was 62%, compared to 64% in the prior year quarter and 57% on a pro forma basis[5] - The company reported a total stockholders' deficit of $298,000 as of September 30, 2025, improved from a deficit of $2.2 million at the end of 2024[15] Revenue and Growth - Q3 2025 thyroid test volume increased by 12% year-over-year, reaching record levels, contributing to thyroid revenue of $8.8 million, up 22% year-over-year[4] - The company anticipates continued growth in revenue, profitability, and cash flow as a thyroid-only clinical diagnostics business[2] Operational Efficiency and Strategy - The company is focused on enhancing operational efficiency through AI and automation as part of its digital strategy[2] - The company continues to develop its unique combination testing platform, including ThyGeNEXT® and ThyraMIR®v2, to support informed patient management decisions[2] Previous Year Comparisons - Net revenue for the three months ended September 30, 2024, was $12,295 million, with a gross profit of $7,902 million[19] - Operating income for the same period was $2,301 million, while net income was $1,676 million[19] - Basic income per share from continuing operations was $0.40, compared to $0.55 in the previous year[19] - Adjusted EBITDA for the three months ended September 30, 2025, was $1,263 million, reflecting a decrease from $2,472 million in the previous year[21] - Total operating expenses for the three months ended September 30, 2024, were $5,601 million, with sales and marketing expenses at $2,864 million[19] - The company reported a loss from discontinued operations of $82 million for the three months ended September 30, 2024[19] - The weighted average number of diluted shares outstanding was 4,423 million[19] - The company incurred interest expenses of $141 million related to note payable for the three months ended September 30, 2024[19] - Research and development expenses were $199 million for the three months ended September 30, 2024[19] Non-GAAP Measures - The company provided non-GAAP financial measures to evaluate ongoing business performance, including Adjusted EBITDA[22]